Your session is about to expire
← Back to Search
CAR T-cell Therapy
CTX120 for Multiple Myeloma
Phase 1
Waitlist Available
Research Sponsored by CRISPR Therapeutics AG
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Eastern Cooperative Oncology Group performance status 0 or 1
Relapsed or refractory multiple myeloma, as defined by IMWG response criteria and treatment with at least 2 prior lines of therapy
Must not have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Upfrom ctx120 infusion up to 60 months post-infusion
Awards & highlights
No Placebo-Only Group
Study Summary
This trial is testing a new drug for safety and effectiveness in patients who have multiple myeloma that has returned after treatment or is resistant to treatment.
Eligible Conditions
- Multiple Myeloma
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowSelect...
You are in good enough physical shape to perform daily activities without assistance.
Select...
You have multiple myeloma that has come back after treatment, and you have already tried at least two different treatments.
Select...
Your kidneys, liver, heart, and lungs are working well.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from ctx120 infusion up to 60 months post-infusion
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from ctx120 infusion up to 60 months post-infusion
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Part A (dose escalation): Incidence of adverse events
Part B (cohort expansion): Objective response rate
Secondary outcome measures
Overall Survival
Progression Free Survival
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: CTX120Experimental Treatment1 Intervention
Administered by IV infusion following lymphodepleting chemotherapy.
Find a Location
Who is running the clinical trial?
CRISPR Therapeutics AGLead Sponsor
7 Previous Clinical Trials
796 Total Patients Enrolled
Annie Weaver, PhDStudy DirectorCRISPR Therapeutics
2 Previous Clinical Trials
347 Total Patients Enrolled
Ewelina Morawa, MDStudy DirectorCRISPR Therapeutics
1 Previous Clinical Trials
227 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You are 18 years old or older.You have had a stem cell transplant from a donor.You had a stem cell transplant less than 60 days ago and are still dealing with serious problems from it.You have received gene therapy, modified cell therapy, or certain types of cancer treatment before.You have a disorder that weakens your immune system or an autoimmune disease that needs strong medication to control.You are in good enough physical condition to perform daily activities without much difficulty.You have a current infection with HIV, hepatitis B, or hepatitis C.You are in good enough physical shape to perform daily activities without assistance.Your kidneys, liver, heart, and lungs are working well.There is evidence that the multiple myeloma has spread to the central nervous system.You have had another type of cancer, except for certain skin or cervix cancers, that was removed completely and has not come back for at least 5 years.You have multiple myeloma that has come back after treatment and have already tried at least two different treatments.You have or had significant brain or nervous system problems, like seizures, stroke, or autoimmune diseases affecting the brain.You have multiple myeloma that has come back after treatment, and you have already tried at least two different treatments.
Research Study Groups:
This trial has the following groups:- Group 1: CTX120
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Does this trial have any open slots for enrollees at the moment?
"The clinicaltrials.gov listing for this medical trial reveals that it is not presently looking to include new candidates, despite having been initially posted on 1/22/2020 and lastly updated on 7/14/2022. Nonetheless, 807 other trials are currently accepting patients at this time."
Answered by AI
How many North American locations are currently conducting this clinical trial?
"As of now, this medical study is accepting patients at 5 select sites. These include the cities of Philadelphia, Chicago and Nashville as well as two other locations. To reduce travel needs, it would be beneficial to register with a clinic located in close proximity."
Answered by AI
Has CTX120 been granted official acceptance by the FDA?
"Our research team has concluded that CTX120 is likely safe, awarding it a score of 1. This assessment was made due to the Phase 1 trial status and limited evidence for efficacy or safety."
Answered by AI
Who else is applying?
What site did they apply to?
University Health Network, Princess Margaret Cancer Centre
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
2
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger